4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Skye Bioscience, Inc. (SKYE) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 2 employees. Its market capitalization is roughly $25 million. In the fiscal year ended 2025-12-31, SKYE reported $0M in revenue and ($56M) in net income.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($58M) | ($36M) | ($14M) | ($12M) | — |
| Net Income | ($56M) | ($27M) | ($38M) | ($20M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($13M) | ($15M) | ($13M) | ($18M) | ($12M) | — |
| Net Income | ($12M) | ($14M) | ($13M) | ($18M) | ($11M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $28M | $73M | $12M | $9M | — |
| Total Liabilities | $8M | $5M | $14M | $12M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SKYE viewer.
About TickerBase · Data methodology & sources